1. Canada Stocks

  2. •

    Health technology

  3. •

    Biotechnology
Biocure Technology Inc.

Biocure Technology Inc.

CCSE:CURE.X
0.06
CAD
-0.01
(-21.43%)
-0.14EPS
1.11MMarket Cap
Biocure Technology Inc.
CSE:CURE.X
(Canadian Securities Exchange)

Recent

price

0.06

P/E

ratio

- -

div

yld

- -

ROIC.AI

2012
2013
2014
2015
2016
2016
2017
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CAD
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Revenue per Share
-0.03
-0.01
0.01
-0.02
-0.02
-0.42
- -
-0.46
-0.62
-0.44
-0.27
-0.1
-0.12
-0.18
-0.03
-0.01
-0.14
Basic EPS, GAAP
-0.07
-0.02
-0.01
-0.01
-0.01
-0.29
-0.01
-0.22
-0.33
-0.35
-0.12
-0.09
-0.07
-0.02
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
0.47
0.46
0.44
0.42
0.41
-0.06
0.39
0.28
0.08
-0.03
-0.18
-0.04
-0.16
0.15
0.13
0.08
-0.03
Book Value per Share
0.47
0.46
0.44
0.42
0.41
-0.06
0.39
0.28
0.08
-0.03
-0.18
-0.05
-0.16
0.15
0.13
0.08
-0.03
Tangible Book Value per Share
3
4
4
4
4
5
5
10
11
11
11
11
12
10
10
16
17
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
-17,053.71
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Operating Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
-2
- -
-5
-7
-5
-3
-1
-1
-2
- -
- -
-2
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
- -
- -
- -
-35,299.35
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
- -
- -
- -
- -
- -
- -
- -
- -
-2
-2
-4
-2
-4
- -
-1
- -
-1
Working Capital
- -
- -
- -
- -
- -
- -
- -
- -
1
3
3
1
- -
- -
- -
- -
- -
LT Debt
2
2
2
2
2
- -
2
3
1
- -
-2
-1
-2
2
1
2
-1
Total Equity
- -
- -
4.4
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
1.97
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
-6.73
-1.87
1.96
-4.43
-3.88
- -
- -
-200.79
-348.32
- -
- -
- -
- -
- -
-17.83
-7.05
- -
Return on Common Equity (%)

Capital Structure

CAD

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
20
20
20
Market Capitalization
2
2
1

Working Capital

CAD

•

in mil. unless spec.
Sep'25
Dec'25
Jun'26
Total Current Assets
- -
- -
- -
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
1
Payables & Accruals
- -
- -
1
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

CAD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-54.33%
-11.55%
17.55%
Free Cash Flow
298.37%
-175.94%
-658%
Net Income, GAAP
5,444.99%
-30.88%
-60.81%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
-0.02
-0.03
2025
- -
- -
- -
- -
-0.01
2026
- -
-0.11
- -
- -
- -

Quarterly Dividends Per Share

CAD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Moderna, Inc. (NASDAQ:MRNA)
Amgen Inc. (NASDAQ:AMGN)
Iovance Biotherapeutics, Inc. (NASDAQ:IOVA)
Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX)
Novavax, Inc. (NASDAQ:NVAX)
10x Genomics, Inc. (NASDAQ:TXG)
Business
Biocure Technology Inc. is a biopharmaceutical company specializing in the development and commercialization of biosimilars and CAR-T cell therapies targeting cancers and other diseases; its core products include biosimilar candidates for Interferon Beta 1b to treat multiple sclerosis, PEG-Filgrastim and Filgrastim for chemotherapy-induced neutropenia and blood disorders, and Ranibizumab for age-related macular degeneration and vision loss; the company also advances proprietary CAR-T cell immunotherapy, notably BCP401, for acute leukemia, chronic lymphocytic leukemia, solid tumors including lung, breast, and pancreatic cancers, with preclinical trials demonstrating high remission rates and low toxicity in animal models. Founded in 2005 and headquartered in Vancouver, Canada, Biocure operates primarily through its South Korean subsidiary Biocure Pharm with research and manufacturing focused in Asia; it maintains joint ventures and partnerships across Asia and Europe for clinical development and planned trials. Recent developments include a December 2024 private placement financing of $200,000 to support operations, an extension of its exclusive letter agreement in 2024 to acquire Atriva Therapeutics GmbH via reverse takeover for respiratory disease assets though the transaction remains pending as of late 2024, and ongoing preclinical advancements for CAR-T therapies with IND submissions targeted for clinical trials.